Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 3, 2014, Pages 240-251

  Osadchii, Oleg E ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

Cardiac arrhythmia; Premature excitation; Ventricular conduction; Ventricular repolarization

Indexed keywords

FLECAINIDE; LIDOCAINE; MEXILETINE; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISPERSION; EVOKED RESPONSE; EXCITATION AND STIMULATION; EXTRASYSTOLE; FEMALE; GUINEA PIG; HEART CONDUCTION; HEART ELECTROPHYSIOLOGY; HEART REPOLARIZATION; HEART VENTRICLE CONDUCTION; MONOMORPHIC VENTRICULAR TACHYCARDIA; NONHUMAN; PRIORITY JOURNAL;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ELECTROPHYSIOLOGICAL PHENOMENA; FEMALE; FLECAINIDE; GUINEA PIGS; HEART VENTRICLES; LIDOCAINE; MEXILETINE; QUINIDINE; SODIUM CHANNEL BLOCKERS; TACHYCARDIA, VENTRICULAR;

EID: 84896319122     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000041     Document Type: Article

References (57)

1. Nattel S, Kneller J, Zou R, et al. Mechanisms of termination of atrial fibrillation by class I antiarrhythmic drugs: Evidence from clinical, experimental, and mathematical modeling studies. J Cardiovasc Electrophysiol. 2003;14(suppl 10):S133-S139
2. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation. 2012;125:381-389
3. Levine JH, Morganroth J, Kadish AH. Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy. Circulation. 1989;80:1063-1069
4. Morganroth J, Goin JE. Quinidine-related mortality in the short-tomedium- term treatment of ventricular arrhythmias. Circulation. 1991; 84:1977-1983
5. Hohnloser SF, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazard of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol. 1995;26: 852-858
6. Almroth H, Andersson T, Fengsrud E, et al. The safety of flecainide treatment of atrial fibrillation: Long-term incidence of sudden cardiac death and proarrhythmic events. J Intern Med. 2011;270:281-290
7. Woosley RL, Wang T, Stone W, et al. Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. Am Heart J. 1984;107:1058-1065
8. Wyman MG, Wyman RM, Cannom DS, et al. Prevention of primary fibrillation in acute myocardial infarction with prophylactic lidocaine. Am J Cardiol. 2004;94:545-551
9. Lewis BH, Antman EM, Graboys TB. Detailed analysis of 24 hour ambulatory electrocardiographic recordings during ventricular fibrillation or torsade de pointes. J Am Coll Cardiol. 1983;2:426-436
10. Kempf FC, Josephson ME. Cardiac arrest recorded on ambulatory electrocardiograms. Am J Cardiol. 1984;53:1577-1582
11. Milner PG, Platia EV, Reid PR, et al. Ambulatory electrocardiographic recordings at the time of fatal cardiac arrest. Am J Cardiol. 1985;56: 588-592
12. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature complexes and sudden death after myocardial infarction. Circulation. 1981;64:297-305
13. Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: Two-year follow-up. Am J Cardiol. 1984;54:31-36
14. Kostis JB, Byington R, Friedman LM, et al. Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. J Am Coll Cardiol. 1987;10:231-242
15. Kuo CS, Munakata K, Reddy P, et al. Characteristics and possible mechanisms of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation. 1983;67:1356-1367
16. Gettes LS, Reuter H. Slow recovery from inactivation of inward currents in mammalian myocardial fibres. J Physiol. 1974;240:703-724
17. Subramanian A, Suszko A, Selvaraj RJ, et al. Modulated dispersion of activation and repolarization by premature beats in patients with cardiomyopathy at risk of sudden death. Am J Physiol Heart Circ Physiol. 2011;300:H2221-H2229
18. Veeraraghavan R, Poelzing S. Mechanisms underlying increased right ventricular conduction sensitivity to flecainide challenge. Cardiovasc Res. 2008;77:749-756
19. Osadchii OE, Soltysinska E, Olesen SP. Na+ channel distribution and electrophysiological heterogeneities in guinea-pig ventricular wall. Am J Physiol Heart Circ Physiol. 2011;300:H989-H1002
20. Boyett MR, Jewell BR. Analysis of the effects of changes in rate and rhythm upon electrical activity in the heart. Prog Biophys Mol Biol. 1980 36:1-52
21. Brahmajothi MV, Morales MJ, Reimer KA, et al. Regional localization of ERG, the channel protein responsible for the rapid component of the delayed rectifier, K+ current in the ferret heart. Circ Res. 1997;81:128-135
22. Bryant SM, Wan X, Shipsey SJ, et al. Regional differences in the delayed rectifier current (IKr and IKs) contribute to the differences in action potential duration in basal left ventricular myocytes in guinea-pig. Cardiovasc Res. 1998;40:322-331
23. Cheng J, Kamiya K, Liu W, et al. Heterogeneous distribution of the two components of delayed rectifier K+ current: A potential mechanism of the proarrhythmic effects of methanesulfonanilide class III agents. Cardiovasc Res. 1999;43:135-147
24. Osadchii O, Norton G, Deftereos D, et al. Rat strain-related differences in myocardial adrenergic tone and the impact on cardiac fibrosis, adrenergic responsiveness and myocardial structure and function. Pharmacol Res. 2007;55:287-294
25. Osadchii OE, Olesen SP. Electrophysiological determinants of hypokalemia-induced arrhythmogenicity in the guinea-pig heart. Acta Physiol (Oxf). 2009;197:273-287
26. Osadchii OE. Quinidine elicits proarrhythmic changes in ventricular repolarization and refractoriness in guinea-pig. Can J Physiol Pharmacol. 2013;91:306-315
27. Soltysinska E, Olesen SP, Osadchii OE. Myocardial structural, contractile and electrophysiological changes in the guinea-pig heart failure model induced by chronic sympathetic activation. Exp Physiol. 2011; 96:647-663
28. Osadchii OE, Woodiwiss AJ, Norton GR. Contractile responses to selective phosphodiesterase inhibitors following chronic beta-adrenoreceptor activation. Pflugers Arch. 2006;452:155-163
29. Conard GJ, Ober RE. Metabolism of flecainide. Am J Cardiol. 1984;53: 41B-51B.
30. Kates RE, Sokoloski TD, Comstock TJ. Binding of quinidine to plasma proteins in normal subjects and in patients with hyperlipoproteinemias. Clin Pharmacol Ther. 1978;23:30-35
31. Benton RE, Sale M, Flockhart DA, et al. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther. 2000;67: 413-418
32. Collinsworth KA, Kalman SM, Harrison DC. The clinical pharmacology of lidocaine as an antiarrhythmic drug. Circulation. 1974;50:1217-1230
33. Routledge PA, Barchowsky A, Bjornsson TD, et al. Lidocaine plasma protein binding. Clin Pharmacol Ther. 1980;27:347-351
34. Pentikainen PJ, Halinen MO, Helin MJ. Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. Eur J Clin Pharmacol. 1983;25:773-777
35. The CAST Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med. 1989;321:406-412
36. Sihm I, Hansen FA, Rasmussen J, et al. Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects. Eur Heart J. 1990;11:145-148
37. Fish FA, Gillette PC, Benson DW. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. J Am Col Cardiol. 1991;18:356-365
38. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. Circulation. 1990;82:1106-1116
39. Ranger S, Nattel S. Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs. Circulation. 1995;92:1300-1311
40. Prystowsky EN. Proarrhythmia during drug treatment of supraventricular tachycardia: Paradoxical risk of sinus rhythm for sudden death. Am J Cardiol. 1996;78:35-41
41. Ng GA. Treating patients with ventricular ectopic beats. Heart. 2006;92: 1707-1712
42. Grant AO, Strauss LJ, Wallace AG, et al. The influence of pH on the electrophysiological effects of lidocaine in guinea-pig ventricular myocardium. Circ Res. 1980;47:542-550
43. Varro A, Elharrar V, Surawicz B. Frequency-dependent effects of several class I antiarrhythmic drugs on Vmax of action potential upstroke in canine cardiac Purkinje fibers. J Cardiovasc Pharmacol. 1985;7:482-492
44. Bigger JT, Mandel WJ. Effect of lidocaine on conduction in canine Purkinje fibers and at the ventricular muscle-Purkinje fiber junction. J Pharmacol Exp Ther. 1970;172:239-254
45. Rosen KM, Lau SH, Weiss MB, et al. The effects of lidocaine on atrioventricular and intraventricular conduction in man. Am J Cardiol. 1970; 25:1-5
46. Campbell TJ, Vaughan Williams EM. Voltage- and time-dependent depression of maximum rate of depolarization of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide. Cardiovasc Res. 1983;17:251-258
47. Hondeghem LM, Matsubara T. Quinidine blocks cardiac sodium channels during opening and slow inactivation in guinea-pig papillary muscle. Br J Pharmacol. 1988;93:311-318
48. Lu HR, Rohrbacher J, Vlaminckx E, et al. Predicting drug- induced slowing of conduction and proarrhythmia: Identifying the bad sodium current blockers. Br J Pharmacol. 2010;160:60-76
49. Yang T, Snyders D, Roden DM. Drug block of IKr: Model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol. 2001;38:737-744
50. Paul AA, Witchel HJ, Hancox JC. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol. 2002; 136:717-729
51. Roden DM, Bennett PB, Snyders DJ, et al. Quinidine delays IK activation in guinea-pig ventricular myocytes. Circ Res. 1988;62:1055-1058
52. Balser JR, Bennett PB, Hondeghem LM, et al. Suppression of timedependent outward current in guinea-pig ventricular myocytes. Actions of quinidine and amiodarone. Circ Res. 1991;69:519-529
53. Wang DW, Kiyosue T, Sato T, et al. Comparison of the effects of class I antiarrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier K+ current of guinea-pig ventricular myocytes. J Mol Cell Cardiol. 1996;28:893-903
54. The Flecainide-Quinidine Research Group. Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial. Circulation. 1983;67:1117-1123
55. Starmer CF, Lastra AA, Nesterenko VV, et al. Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments. Circulation. 1991;84:1364-1377
56. Osadchii OE. Flecainide-induced proarrhythmia is attributed to abnormal changes in repolarization and refractoriness in perfused guinea-pig heart. J Cardiovasc Pharmacol. 2012;60:456-466
57. Osadchii OE. Impact of Na+ channel blockers on transmural dispersion of refractoriness and arrhythmic susceptibility in guinea-pig left ventricle. Eur J Pharmacol. 2012;691:173-181